Kiniksa Pharmaceuticals International Plc (KNSA)

Mar 24, 2025

Kiniksa CFO Mark Ragosa sells shares worth $368,465 By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

Kiniksa CFO Mark Ragosa sells shares worth $368,465 - Investing.com India

Mar 24, 2025

Mar 19, 2025

Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock - Investing.com

Mar 19, 2025

Mar 18, 2025

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at Citigroup - MarketBeat

Mar 18, 2025

Mar 17, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 9,051 Shares - MarketBeat

Mar 17, 2025

Mar 17, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average Target Price from Analysts - MarketBeat

Mar 17, 2025

Mar 17, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells $809,277.00 in Stock - MarketBeat

Mar 17, 2025

Mar 16, 2025

Globeflex Capital L P Boosts Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat

Mar 16, 2025

Mar 16, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 17,118 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat

Mar 16, 2025

Mar 15, 2025

Kiniksa Pharmaceuticals CFO Mark Ragosa sells $809k in shares By Investing.com - Investing.com Canada

Mar 15, 2025

Mar 14, 2025

Kiniksa Pharmaceuticals CAO Michael Megna sells shares worth $203,194 By Investing.com - Investing.com Australia

Mar 14, 2025

Mar 14, 2025

Kiniksa Pharmaceuticals CAO Michael Megna sells shares worth $203,194 - Investing.com India

Mar 14, 2025

Mar 14, 2025

Kiniksa Pharmaceuticals CFO Mark Ragosa sells $809k in shares - Investing.com

Mar 14, 2025

Mar 14, 2025

Kiniksa Pharmaceuticals Executives Sell Shares - TradingView

Mar 14, 2025

Mar 14, 2025

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now - Mitrade

Mar 14, 2025

Mar 14, 2025

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now - The Motley Fool

Mar 14, 2025

Mar 13, 2025

Taking on analysts’ expectations and winning: Kiniksa Pharmaceuticals International Plc (KNSA) - SETE News

Mar 13, 2025

Mar 13, 2025

Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target - Marketscreener.com

Mar 13, 2025

Mar 12, 2025

Kiniksa Pharmaceuticals COO sells shares worth $261,333 - Investing.com

Mar 12, 2025

Mar 12, 2025

Kiniksa Pharmaceuticals COO sells shares worth $261,333 By Investing.com - Investing.com UK

Mar 12, 2025

Mar 07, 2025

Deeper Dive: Understanding Kiniksa Pharmaceuticals International Plc (KNSA) Through its Various Ratios - The Dwinnex

Mar 07, 2025

Mar 06, 2025

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst - Benzinga

Mar 06, 2025

Mar 06, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? - Insider Monkey

Mar 06, 2025

Mar 06, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers - Defense World

Mar 06, 2025

Mar 05, 2025

New York State Common Retirement Fund Has $302,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World

Mar 05, 2025

Mar 05, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Large Increase in Short Interest - Defense World

Mar 05, 2025

Mar 03, 2025

10 Best UK Growth Stocks to Buy Now - Insider Monkey

Mar 03, 2025

Mar 02, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey

Mar 02, 2025

Mar 02, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? - Yahoo Finance

Mar 02, 2025

Feb 28, 2025

12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey

Feb 28, 2025

Feb 28, 2025

Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus.com

Feb 28, 2025

Feb 27, 2025

Kiniksa Pharmaceuticals Shifts Strategic Focus with Key Agreement Terminations and 2024 Financial Results - Defense World

Feb 27, 2025

Feb 26, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 26, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Q4 2024 Earnings: Revenue at $122.5M, Mi - GuruFocus.com

Feb 25, 2025

Feb 25, 2025

Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab - MSN

Feb 25, 2025

Feb 25, 2025

Big Pipeline Updates From Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Seeking Alpha

Feb 25, 2025

Feb 25, 2025

Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 - Investing.com India

Feb 25, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases -February 25, 2025 at 08:20 am EST - Marketscreener.com

Feb 25, 2025

Feb 25, 2025

Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 By Investing.com - Investing.com South Africa

Feb 25, 2025

Feb 25, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M - Marketscreener.com

Feb 25, 2025

Feb 25, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss - Marketscreener.com

Feb 25, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution - The Manila Times

Feb 25, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Reports Strong Q4 2024 Financials with ARCALYST Revenue of $417 Million and Anticipates 2025 Sales Growth - Nasdaq

Feb 25, 2025

Feb 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

Can Kiniksa's 79% Revenue Surge Continue as Company Shifts Pipeline Focus? - StockTitan

Feb 25, 2025

Feb 25, 2025

Can Kiniksa's New Pericarditis Drug Build on Its $800M ARCALYST Success? - StockTitan

Feb 25, 2025

Feb 24, 2025

KNSAKiniksa Pharmaceuticals International, plc Latest Stock News & Market Updates - StockTitan

Feb 24, 2025

Feb 21, 2025

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire

Feb 21, 2025

Feb 14, 2025

Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN

Feb 14, 2025

Feb 14, 2025

Kiniksa Pharmaceuticals COO sells shares worth $273,980 - MSN

Feb 14, 2025

Feb 13, 2025

Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain - Seeking Alpha

Feb 13, 2025

Feb 13, 2025

Kiniksa Pharmaceuticals COO sells shares worth $273,980 By Investing.com - Investing.com Canada

Feb 13, 2025